Browse our complete Parkinson Disease Treatment range — 10 WHO-GMP certified medications covering every major drug class used to manage motor symptoms, slow disease progression, and reduce levodopa-induced dyskinesia.
Levodopa + carbidopa combinations remain the cornerstone of therapy: Syndopa (immediate-release) and Syndopa CR (controlled-release) deliver dopamine’s biochemical precursor across the blood–brain barrier where surviving neurones convert it back to dopamine, with carbidopa preventing peripheral breakdown so far less levodopa is needed and side effects are reduced.
Non-ergot dopamine agonists directly stimulate D2/D3 dopamine receptors and are first-line in younger patients to delay levodopa-induced dyskinesia: Ropark (ropinirole), Pramirol (pramipexole) and Trivastal LA (piribedil 50 mg long-acting). These agents do not carry the cardiac valve fibrosis risk associated with the ergot agonist Brom (bromocriptine), which still has a role in Parkinson disease, hyperprolactinaemia and acromegaly.
MAO-B inhibitors slow the brain’s breakdown of dopamine: Selgin (selegiline 5 mg, monotherapy or adjunct), Rasalect (rasagiline 1 mg, once-daily, no amphetamine metabolites) and Xafinact (safinamide 50–100 mg, adjunct only, with a unique additional glutamate-modulating action that helps levodopa-induced dyskinesia).
The NMDA antagonist + dopamine releaser Amantrel (amantadine 100 mg) is one of the only agents that directly reduces levodopa-induced dyskinesia in advanced disease, and is also useful as monotherapy in early Parkinson disease.
Every product in this category is sourced from WHO-GMP gecertificeerde fabrikanten, shipped worldwide in discreet packaging, with detailed clinical content covering mechanism, dosing, motor-fluctuation management, drug interactions, impulse-control safety counselling and the specific cautions for each drug class. Need help choosing? See the comparison panels on each product page or contact our customer care team.